Isotype
Whole Humanized Antibody
Description
CDC-Enhanced Palivizumab is a Fc-modified anti-RSV therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Palivizumab, Palivizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Infections, Respiratory Syncytial Virus
Classification
Therapeutic antibody; biobetter
Patent
Blinatumomab was first received FDA approval in 2000. The patent expired in the United States in 2015.
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Palivizumab . For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
cytotoxic T-lymphocyte associated protein 4
Background
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
Alternative Names
CD; GSE; GRD4; ALPS5; CD152; RSV; IDDM12; CELIAC3
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB00110 (BTD00097, BIOD00097)
Antibody Isotype
Whole Humanized Antibody
Description
Palivizumab is a humanized monoclonal antibody (IgG) that targets the epitope of the RSV F protein A antigenic site. It is used to prevent respiratory syncytial virus (RSV) infection. Palizumab was approved for medical use in 1998.
Indication
Infections, Respiratory Syncytial Virus
